ClinicalTrials.gg
CompletedNCT03755557Updated Oct 12, 2020

Demonstration of Equivalence and Early Onset of a Novel Anti-allergic Nasal Spray Compared to Marketed Nasal Spray

A Phase 3 interventional study of Rhinocort and Budesolv in Allergic Rhinitis, Allergic Conjunctivitis and Hayfever, sponsored by Marinomed Biotech AG. Completed at 1 site in Austria. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-10-12.

Primary conditionRhinitis, Allergic, SeasonalRegistry: Rhinitis, AllergicReclassifiedWhy we changed it
Registry
Rhinitis, Allergic — the first condition term the registry derived for this study.
ClinicalTrials.gg
Rhinitis, Allergic, Seasonal
Why
  1. The study's listed conditions name Rhinitis, Allergic, Seasonal, a narrower term within Rhinitis, Allergic.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Marinomed Biotech AG · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
82
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies in Rhinitis, Allergic, Seasonal with a site in Austria — none open to participants now, none under way, none of them phase 3. Rhinitis, Allergic, Seasonal · Austria.

Enrollment
5th of 17
82 · median 70
Started
2018
the only one that year
Phase 3
3 of 17
none open now
Registered
14th of 17
by date
Lead sponsor
1 of 17
Marinomed Biotech AG

Among the 17 studies in Rhinitis, Allergic, Seasonal with a site in Austria, this one is the 5th largest by enrollment, is the only one that started in 2018, is one of 3 in phase 3, and was the 14th registered.

Rhinitis, Allergic, Seasonal

404 studies on the registry are indexed under Rhinitis, Allergic, Seasonal; 24 are open to participants now.

Browse Rhinitis, Allergic, Seasonal studies →

Open to participants now

None of the 17 studies in Rhinitis, Allergic, Seasonal with a site in Austria is open now. The open studies under Rhinitis, Allergic, Seasonal, anywhere →

Who these studies take

Of the 17 Rhinitis, Allergic, Seasonal studies recruiting now, 2 (12%) set no upper age limit and 15 (88%) stop at 75 or younger; 1 takes children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 17 studies in Rhinitis, Allergic, Seasonal with a site in Austria as a file.
02

Study summary

Intranasal corticosteroids are accepted as safe and effective first-line therapy for allergic rhinitis, especially in treatment of persistent symptoms.

Budesonide, a non-halogenic glucocorticoid, is widely used in the management of inflammatory mucosal diseases like chronic obstructive pulmonary disease, asthma and allergic rhinitis. It is a highly fat-soluble substance with low water solubility and is presented as dispersion in marketed nasal sprays, like Rhinocort aqua 64. The maximum therapeutic efficacy of Rhinocort aqua is obtained after an application period of 7 to 14 days. In Budesolv, the solubility of budesonide is considerably increased suggesting that the same therapeutic efficacy can be reached with a lower dose. Better bioavailability of the dissolved drug promise an earlier onset of therapeutic efficacy. The current trial is undertaken to demonstrate these two effects. Subjects suffering from grass pollen allergic rhinitis will be challenged with grass pollen in a challenge chamber.

Allergic subjects will be treated with two actuations (50 μl) of respective study treatment into each nostril once daily for 8 days. The total daily budesonide dose will be 40 μg per subject for Budesolv 10 and 256 μg per subject for Rhinocort® aqua 64. The primary objective of the study is to show non-inferiority of Budesolv 10 to Rhinocort® aqua 64. On day 8 grass pollen allergic patients will be challenged with grass pollen over a period of 6 hours and subjective nasal symptoms (congestion, sneezing, itching, rhinorrhea) as well as objective symptoms (nasal airflow, nasal secretion) will be assessed every 15 minutes.

The second objective of the trial is to demonstrate an early on-set of therapeutic efficacy of Budesolv 10 compared to Rhinocort aqua. On day 1, grass pollen allergic patients will be challenged with grass pollen allergen in the challenge chamber over a period of 6 hours. After 1 hour 45 minutes, patients will receive their first dosage of the respective nasal spray treatment. During the 6 hour grass pollen challenge, subjective and objective endpoints will be measured every 15 minutes.

To eliminate an individual bias based on expectations, the effect and onset of action is also compared to the effects of a suitable placebo. The same set of study participants will receive all three interventions in three consecutive treatment periods.

Read the detailed description

This is a randomized, placebo controlled, three way cross over, double-blind, single site trial in adult subjects (18 years of age and older) who demonstrate grass specific Immunglobulin E (IgE) reactivity and have a history of grass pollen induced allergic rhinitis/rhinoconjunctivitis with or without controlled asthma. In the cross-over setting three treatments, namely placebo, Budesolv 10 or Rhinocort® aqua 64 will be evaluated.

The primary objective of the trial is to demonstrate therapeutic equivalence/non-inferiority between Budesolv 10 and Rhinocort® aqua 64, a marketed comparator containing the same compound (budesonide), in patients suffering from grass pollen induced allergic rhinitis/rhinoconjunctivitis with or without controlled asthma on day 8 of treatment. A placebo group will be introduced to show effectiveness of treatment and hence validate the trial design.

The evaluation will be based on the assessment of rhinitis symptoms during grass pollen challenge performed in the Vienna Challenge Chamber (environmental exposure chamber).

Secondary objective of the trial is the early onset of action of Budesolv 10 compared to Rhinocort® aqua 64, determined on day one of treatment.

Visit 1 + 2 - Screening + Inclusion period:

Subjects will be screened for appropriate allergic response. A total nasal symptom score (TNSS) of at least 6 points out of 12 within the first two hours in the grass pollen challenge chamber is required to be included into the study.

Visit 3 + 5 + 7 / "day 1":

Eligible subjects will be randomly assigned to one of the three treatment arms (fully blinded) in the order of their screening numbers assigned at visit 1. Subjects will enter the study site about one hour ahead of the start of allergen provocation. After positive completion of all study relevant assessments, subjects enter the grass pollen challenge chamber for subjective and objective assessments for a period of 6 hours. One hour forty-five minutes after entry, the first treatment will be applied.

The subjective nasal symptom score will be recorded every fifteen minutes during a 6-hour allergen exposure challenge. Every hour rhinomanometry will be performed to objectively evaluate the respiratory function of the nose. Additional rhinomanometry will be performed at two hours 30 minutes after entry. Subjects will continue treatment with two actuations into each nostril once a day until day 7.

Visit 4 + 6 + 8 / "day 8":

On day 8 of their respective treatment block, subjects will enter the study site about two hours before provocation will start. Subjects will take their last treatment dosage approximately one hour before entering the challenge chamber. The study medication device will be returned to study site staff for external analytical evaluations after usage (in-use-stability test). After receiving their last treatment dose and shortly before entering the challenge chamber, baseline symptom score will be assessed. Like on day one, subjects will be provoked for 6 hours with grass pollen allergens. Subjective symptom scores will be recorded every fifteen minutes, and rhinomanometry will be performed every hour during the challenge.

Between the respective study treatments, a wash-out period of at least 20 days must be adhered to allowing complete dissipation of the previous treatment. After the wash-out period, subjects change to the next treatment block in the sequence. During the entire trial, subjects will be asked to monitor for adverse events (AEs), and they will record the use of concomitant medications on the provided form. Female subjects of child-bearing potential will complete a urine pregnancy test in the course of all visits.

Following parameters will be assessed:

  • Subjective symptom score (nasal, ocular, respiratory) during a grass pollen challenge lasting for 6 hours - every 15 minutes Active anterior rhinomanometry (AAR) - every 60 minutes, additional measurement on day 1 at 2:30 after entry.
  • Lung function tests using regular spirometry for FEV1 and FVC - every 120 minutes
  • Nasal secretion weight - every 30 minutes
  • Physical examination - at Screening and Follow up
  • Vital signs - every visit, pre- and post-challenge
  • Safety laboratory assessments: Complete blood count with differential, blood chemistry, liver function, urine dipstick test - at screening and last treatment visit, serology at screening and drug abuse test on investigator's decision
  • Skin Prick Test with skin prick test solution (Manufacturer Allergopharma) - at Screening or within the previous 6 months
  • Specific CAP analysis (g6) - at Screening or within the previous 6 months
  • ECG - at screening and Follow up
  • Adverse events - throughout the study
  • Concomitant medication - throughout the study One week after the final provocation session, subjects will complete the trial after their follow up visit. Validated methods of data collection, analysis, and evaluation will be used for the trial.

The trial endpoints are listed below:

Primary efficacy endpoint:

The primary efficacy endpoint will be the mean 'Total Nasal Symptom Score' (TNSS), calculated as the baseline adjusted mean of TNSS measured at 17 time points (every 15 minutes) during the grass pollen allergen exposure challenge from time point 2 to 6 hours on day 8.

The TNSS is the sum of the symptoms "nasal congestion", "rhinorrhea", "itchy nose" and "sneezing". Each individual symptom will be scored on a 4-point categorical scale from 0-3 (where "0"= none "1"=mild "2"=moderate "3"=severe).

Key Secondary efficacy endpoint:

Time point when onset of action can be observed.

Additional secondary efficacy endpoints:

  • Nasal airflow: will be assessed every hour during the six hour grass pollen allergen exposure challenge
  • Nasal secretion: will be assessed every 30 minutes during the six-hour grass pollen allergen exposure challenge. Additional rhinomanometry will be done on day 1 at 2:30 h after entry in the challenge chamber
  • Total ocular symptom score (TOSS) is the sum of the symptoms "ocular itching", "redness", "watery eyes".
  • Total asthma symptom score (TASS) is the sum of the symptoms "cough", "wheeze", "dyspnea".

Each individual symptom of TOSS and TASS will be scored on a 4-point categorical scale from 0-3 (where "0"= none "1"=mild "2"=moderate "3"=severe). TOSS and TASS will be assessed every 15 minutes during the six-hour grass pollen allergen exposure challenge.

Safety endpoints:

  • Adverse events (AEs)
  • Safety laboratory
  • ECG
  • Spirometry (FeV1, FVC)
03

Conditions studied

  • Allergic Rhinitis
  • Allergic Conjunctivitis
  • Hayfever

Keywords

  • budesonide
  • allergic rhinitis
  • allergic rhinoconjuntivitis
  • allergen exposure chamber
  • onset of action
  • therapeutic equivalence
  • total nasal symptom score
  • hayfever
  • glucocorticosteroids
  • nasal congestion
  • Vienna Challenge Chamber
  • Carragelose
  • Carrageenan
  • Iota-Carrageenan
04

In context

Rhinitis, Allergic, Seasonal Reclassified

404 studies on the registry are indexed under Rhinitis, Allergic, Seasonal; 24 are open to participants now.

This study's enrollment of 82 is below the median of 131 across 366 interventional studies indexed under Rhinitis, Allergic, Seasonal.

Browse Rhinitis, Allergic, Seasonal studies →

Lead sponsor

Marinomed Biotech AG is the lead sponsor of 8 studies on the registry; none are open to participants now.

Compared within Rhinitis, Allergic, Seasonal, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Rhinitis, Allergic. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

A subject will be eligible for inclusion in this study only if all of the following criteria apply:

  • Written obtained before any trial related procedures are performed
  • Healthy male or female subjects aged 18 years or older
  • Female subjects of must have a negative pregnancy test and be willing to practice appropriate methods until the end of treatment visit
  • A documented allergic history of moderate to severe SAR to grass pollen for the previous two years
  • Subjects exhibit a moderate to severe response to approximately 1500 grass pollen grains/m3 within the first 2 hours in the Vienna Challenge Chamber, which is defined as total nasal symptom score (TNSS) of at least 6 (out of 12) using standard VCC grass pollen allergen mixture. Nasal symptom score is the sum of "nasal congestion", "rhinorrhea", "itchy nose" and "sneezing", each of which have been scored on a categorical scale from 0 to 3.
  • Positive Skin Prick Test (SPT) response (wheal diameter at least 3 mm larger than diluent control) to grass pollen SPT solutions (standard Allergopharma) at screening or within the last 6 months prior to study start.
  • Positive serum specific IgE against recombinant major allergen components of the used grass pollen (specific CAP IgE ≥0.70 kU/L) at screening or within the last 6 months prior to study start.
  • Patients with a body weight of ≥ 50kg and a within the range of 19-30kg/m2.
  • Non-smoking subjects (smoked \<10 packs years in their lifetime and had not smoked in the last 6 months)
  • Asthma patients only if the asthma condition is mild or intermittent, and if those are not treated with
  • Subject has a (FEV1) of at least 80% of predicted value (ECCS) at the screening.
  • Subject is capable of understanding the study procedures and potential risks associated with the study, and voluntarily agrees to participate by giving written informed consent.
  • Subject is able to adhere to dose and visit schedules.
  • Subject is able to read, understand and complete questionnaires and diaries.

Exclusion criteria

Exclusion Criteria

A subject will not be eligible for inclusion in this study if any of the following criteria apply:

  • Pregnant, lactating or sexually active women with who are not using a medically accepted method (pregnancy to be controlled by a pregnancy dipstick test).
  • A clinical history of uncontrolled asthma within 3 months prior to screening.
  • Subjects with asthma requiring treatment with inhaled on a regular basis judged by the investigator.
  • Previous successful immunotherapy to grass pollen, a grass pollen allergen or a cross-reacting allergen within the past 3 years.
  • Ongoing treatment with any allergen-specific immunotherapy product.
  • Subjects with a current oral candidiasis infection or treatment for oral candidiasis during the last 30 days before starting the study.
  • Subjects with history of tuberculosis.
  • Subjects with any fungal/viral/bacterial respiratory or systemic infections during the last 30 days.
  • Symptoms of or treatment for upper respiratory tract infection, acute sinusitis, acute otitis media or other relevant infectious process at randomization.
  • nasal polyps, medical history of paranasal sinus surgery and/or medical history of surgery of nasal turbinates judged by the investigator.
  • Subjects with glaucoma or a family history of glaucoma.
  • Subjects using any ophthalmic steroids during the last 30 days.
  • Subjects treated with nasal, inhaled or systemic steroids during the last 30 days.
  • History of anaphylaxis with cardiorespiratory symptoms (immunotherapy, exercise induced, food allergy, drugs or an idiopathic reaction).
  • Any clinically relevant chronic disease judged by the investigator.
  • Systemic disease affecting the immune system judged by the investigator.
  • Use of an drug within 30 days/5 half-lives of the drug (which ever longest) prior to screening.
  • History of allergy, or intolerance to any ingredients of the IMP.
  • History of alcohol or drug abuse.
  • Being immediate family of the investigator or trial staff, defined as the investigator's/staff's spouse, parent, child, grandparent or grandchild.
  • Subjects with previous SAR that has proven unresponsive to steroid therapy.
  • Subjects treated with leukotriene antagonists (1 month before study start), long-lasting anti-histamines, like cetirizine, fexofenandine, loratadine, desloratadine, hydroxyzine (5 to 10 days before study start), mast cell stablizier (2 weeks before study start) or nasal decongestant (3 days before study start).
  • Subjects with an acute or chronic sinusitis judged by the investigator.
  • Subjects with hypersensitivity to corticosteroids judged by the investigator.
  • Subjects with ocular herpes simplex infections.
  • Subjects with cataracts and with cataract history.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
82 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Application of a placebo nasal spray once daily for 8 days Nasal Sprays

    Other: Placebo

  • Active comparator
    Rhinocort

    Nasal Sprays Application of "Rhinocort Aqua 64 micrograms, nasal spray" once daily for 8 days. Daily dosage 256 µg/d

    Drug: Rhinocort

  • Experimental
    Budesolv

    Application of a Budesolv 10 micrograms, nasal spray once daily for 8 days. Daily dosage 40 µg/d Nasal Sprays

    Drug: Budesolv

Interventions

  • Application of a nasal spray

    Also known as: Budesonide

  • Application of a nasal spray

    Also known as: Budesonide

  • OtherPlacebo

    Application of a nasal spray

    Also known as: buffered saline

07

What researchers measure

Primary outcomes

  1. Total Nasal Symptom Score

    subjective compound score evaluating "nasal congestion", "rhinorrhea", "itchy nose" and "sneezing" from "0" (absent) to "3" (severe). The sum of sub-scores is reported as total nasal symptom score (0 - 12)

    Time frame: 2 - 6 hours of allergen challenge

Secondary outcomes

  1. Total Ocular Symptom Score

    subjective compound score evaluating "ocular itching", "redness", "watery eyes" from "0" (absent) to "3" (severe). The sum of sub-scores is reported as total ocular symptom score (0 - 9)

    Time frame: 2 - 6 hours of allergen challenge

  2. Total Asthma Symptom Score

    subjective compound score evaluating "cough", "wheeze", "dyspnea" from "0" (absent) to "3" (severe). The sum of sub-scores is reported as total asthma symptom score (0 - 9)

    Time frame: 2 - 6 hours of allergen challenge

  3. Nasal airflow

    Rhinomanometry

    Time frame: 0 - 6 hours of allergen challenge

  4. Nasal secretion

    tissue weight

    Time frame: 0 - 6 hours of allergen challenge

08

Study locations

1 site
  • Vienna Challenge Chamber
    Vienna, 1140, Austria
09

References and documents

Publications

  • Murdoch RD, Bareille P, Ignar D, Miller SR, Gupta A, Boardley R, Zieglmayer P, Zieglmayer R, Lemel P, Horak F. The improved efficacy of a fixed-dose combination of fluticasone furoate and levocabastine relative to the individual components in the treatment of allergic rhinitis. Clin Exp Allergy. 2015 Aug;45(8):1346-55. doi: 10.1111/cea.12556. PubMed 25900517 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2018 to primary completion in Apr 2019, 4 months.

Of 31 industry-sponsored phase 3 interventional studies under Rhinitis, Allergic, Seasonal, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 14. This study's 4 months is close to that.

Counting every sponsor, half of 37 studies reached it within 4 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2018
First posted
Nov 28, 2018
StartActual
Nov 19, 2018
Primary completionActual
Apr 5, 2019
CompletionActual
Apr 5, 2019
Last update
Oct 12, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 12, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03755557
Lead sponsor
Marinomed Biotech AG
Responsible party
Sponsor
First posted
Nov 28, 2018
Start date
Nov 19, 2018
Primary completion
Apr 5, 2019
Completion
Apr 5, 2019
Last update
Oct 12, 2020

Study contacts

Eva E Prieschl-Grassauer, PhD
study chair · Marinomed Biotech AG

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Budesonide

Start the discussion